

## OSE Pharma announces its events for Q1 2016

Paris, January 5<sup>th</sup>, 2016, 5:45 PM – OSE Pharma SA (ISIN: FR0012127173; Ticker: OSE), an immunology company developing a T-specific immunotherapy for late-stage cancer patients, will attend the following investor and bio-partnering events during Q1 2016.

<b>Biotech Showcase™ Annual Conference</b>	11 – 13 January, San Francisco, CA, USA
<b>BioMed EVENT by Invest Securities</b>	27 January, Paris, France
<b>BIO CEO &amp; Investor Conference</b>	8 - 9 February, New York City, NY, USA
<b>European MidCap Event</b>	17 February, Frankfurt, Germany
<b>Annual European Life Science CEO Forum &amp; Exhibition Forum</b>	15 - 16 March, Zurich, Switzerland

### ABOUT OSE PHARMA

OSE Pharma is a biotech company that designs and develops cancer immunotherapy treatments using its Memopi® technology, through “neo-epitopes” (small synthetic peptides chemically modified to increase the binding the HLA A2 or TCR receptors) which triggers a cytotoxic T-cell response and leads the immune system to destroy cancer cells. More than 10,000 epitopes were selected.

Its lead product Tedopi® (OSE-2101) combines 10 optimized “neo-epitopes” simultaneously acting against 5 tumor-associated antigens (TAAs). These 5 antigens have been selected because they are a factor of poor prognosis in several types of cancers. The 10 optimized “neo-epitopes” have been selected and modified to enhance their binding to HLA-A2 and TCR receptors, and trigger a stronger T-cell response. These strong cytotoxic T-cell responses lead the immune system to destroy tumor cells expressing HLA-A2 antigens and one of the targeted tumor antigens (TCR).

The most advanced clinical stage of Tedopi® is a pivotal Phase 3 study to be launched soon in Europe and in the U.S. in patients diagnosed with non-small cell lung cancer (NSCLC). It will target patients whose cells are expressing HLA-A2 antigens, a key receptor for the cytotoxic T-immune response that can be found in nearly 45% of patients with lung cancer. Patients expressing the HLA-A2 positive receptor are those responsive to Tedopi®. The trial will focus on patients with stage IIIb (invasive) or stage IV (metastatic) NSCLC after at least one first line therapy failure. Its objective will be to evaluate the benefits of Tedopi® compared to current standard chemotherapy treatments (docetaxel or pemetrexed) in this patient population. The primary endpoint of this trial will be overall survival (the Phase 2 study demonstrated a long survival of patients, considering how advanced their pathology was). 500 patients will be included in Europe and in the U.S.

Tedopi® can be developed in Phase 2 in combination with other immunotherapeutic products or targeted therapies. It is also considered for other oncology indications (ovary, colon, prostate, breast) for HLA-A2 positive patients.

OSE Pharma is listed on Euronext Paris (ISIN: FR0012127173; Ticker: OSE).  
For more information, please visit [www.osepharma.com](http://www.osepharma.com)



Follow us on Twitter @OSE\_Pharma

## Press contacts

### **OSE Pharma sa**

Dominique Costantini, CEO

[dominique.costantini@osepharma.com](mailto:dominique.costantini@osepharma.com)

Mob +33 6 13 20 77 49

Alexis Peyroles, CFO/BD

[Alexis.peyroles@osepharma.com](mailto:Alexis.peyroles@osepharma.com)

Mob : +33 6 11 51 19 77

### **Citigate Dewe Rogerson**

Laurence Bault / Lucie Larguier

[laurence.bault@citigate.fr](mailto:laurence.bault@citigate.fr)

+33 1 53 32 84 78

### **Alize RP**

Florence Portejoie

[fportejoie@alizerp.com](mailto:fportejoie@alizerp.com)

+33 6 47 38 90 04

### Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to OSE Pharma and its activity. Although OSE Pharma's management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from OSE Pharma's results, financial conditions, performance or achievements expressed, projected or implied by such information and forward-looking statements.

Other than as required by applicable law (article 223-1 et seq. of the General Regulation of the AMF), OSE Pharma issues this press release at the date hereof and does not undertake any obligation to update or revise any forward-looking information or statements.

These risks and uncertainties include among other things, the uncertainties inherent in future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives,

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-056 on September, 17th 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus approved by the AMF under number 15-078 on 6th March 2015, which can be found on the websites of the AMF ([www.amf-france.org](http://www.amf-france.org)) and of OSE Pharma ([www.osepharma.com](http://www.osepharma.com)).